These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 26547918

  • 1. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.
    Papp KA, Armstrong AW, Reich K, Karunaratne M, Valdecantos W.
    Am J Clin Dermatol; 2016 Feb; 17(1):79-86. PubMed ID: 26547918
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis.
    Prussick R, Unnebrink K, Valdecantos WC.
    J Drugs Dermatol; 2015 Aug; 14(8):864-8. PubMed ID: 26267731
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, Landells I, Hoeger P, Kotkin C, Unnebrink K, Seyger M, Williams D.
    Lancet; 2017 Jul 01; 390(10089):40-49. PubMed ID: 28478975
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar 01; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 5. Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab.
    Armstrong AW, Villanueva Quintero DG, Echeverría CM, Gu Y, Karunaratne M, Reyes Servín O.
    Am J Clin Dermatol; 2016 Dec 01; 17(6):691-699. PubMed ID: 27815915
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.
    Am J Clin Dermatol; 2011 Feb 01; 12(1):51-62. PubMed ID: 21110526
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM.
    J Am Acad Dermatol; 2010 Sep 01; 63(3):448-56. PubMed ID: 20605254
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
    Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W.
    Br J Dermatol; 2008 Sep 01; 159(3):513-26. PubMed ID: 18627372
    [Abstract] [Full Text] [Related]

  • 9. Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis.
    Navarini AA, Poulin Y, Menter A, Gu Y, Teixeira HD.
    J Drugs Dermatol; 2014 May 01; 13(5):554-62. PubMed ID: 24809878
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
    Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE.
    Value Health; 2018 Jan 01; 21(1):1-8. PubMed ID: 29304933
    [Abstract] [Full Text] [Related]

  • 12. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J.
    Arch Dermatol; 2011 Apr 01; 147(4):429-36. PubMed ID: 21173304
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP, Chimenti S, Reich K, Gniadecki R, Sprøgel P, Unnebrink K, Kupper H, Goldblum O, Thaçi D.
    J Eur Acad Dermatol Venereol; 2011 Sep 01; 25(9):1012-20. PubMed ID: 21214631
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB.
    J Am Acad Dermatol; 2017 Mar 01; 76(3):405-417. PubMed ID: 28057360
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.
    JAMA Dermatol; 2018 Jun 01; 154(6):676-683. PubMed ID: 29799960
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
    Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A, CHAMPION Study Investigators.
    Br J Dermatol; 2008 Mar 01; 158(3):558-66. PubMed ID: 18047523
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
    Inzinger M, Heschl B, Weger W, Hofer A, Legat FJ, Gruber-Wackernagel A, Tilz H, Salmhofer W, Quehenberger F, Wolf P.
    Br J Dermatol; 2011 Sep 01; 165(3):640-5. PubMed ID: 21564068
    [Abstract] [Full Text] [Related]

  • 18. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C, Creighton-Smith M, Sorensen EP, Dumont N, Gottlieb AB.
    J Drugs Dermatol; 2015 Aug 01; 14(8):881-6. PubMed ID: 26267734
    [Abstract] [Full Text] [Related]

  • 19. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P, Richter L, Saxinger W, Vasiljevic M, Stingl G.
    J Eur Acad Dermatol Venereol; 2015 Sep 01; 29(9):1742-9. PubMed ID: 25665143
    [Abstract] [Full Text] [Related]

  • 20. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM.
    Br J Dermatol; 2010 Oct 01; 163(4):838-46. PubMed ID: 20649798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.